research Cemotherapi Induce Alopecia Due Carboplatin-Paclitaxel Regiment
Chemotherapy with carboplatin-paclitaxel causes hair loss in all patients.
Search
for
Sort by
Research
30 / 1000+ results 
research INDIVIDUAL ARTICLE: USCOM V: A Practical Algorithm for the Prevention and Treatment of Cutaneous Side Effects of Hormonal Cancer Therapy
A new method helps manage skin side effects from hormonal cancer therapy, improving patient care.
research EXPERIENCE OF A PRIVATE HOSPITAL IN THE FEDERAL DISTRICT IN CRYOTHERAPY WITH A HYPOTHERMAL CAP FOR PATIENTS USING PACLITAXEL 80 MG/M² WEEKLY FOR 12 WEEKS
Scalp cooling therapy helped over 80% of women keep at least half their hair during chemotherapy.
research Index
Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.
research Limitations of Treatment-Induced Alopecia Grading Instruments in Evaluating Therapeutic Response
Current methods for grading hair loss from cancer treatment are not accurate enough and need improvement.
research Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
research Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies
Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.
research The management of EGFR inhibitor adverse events: a case series and treatment paradigm
Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
research Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
Skin side effects from cancer treatments can lead to changes in therapy and are common, with nail changes being the most frequent.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
research Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
Understanding and managing side effects of hedgehog pathway inhibitors can improve treatment for advanced basal cell carcinoma.
research Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Afatinib often causes skin problems that need proactive management.
research Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
Targeted anticancer therapies in children often cause skin side effects like rash and dry skin.
research Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.
research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
Skin side effects from melanoma immunotherapy are common and may indicate better survival.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review
Early detection and multidisciplinary management of skin and mouth side effects from breast cancer treatments improve patient outcomes.
research Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
research Platelet-Rich Plasma and Its Utilities in Alopecia: A Systematic Review
Platelet-rich plasma (PRP) treatment has been found effective in promoting hair growth for alopecia patients, with minimal side effects like temporary pain and redness.
research Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
Sorafenib after liver surgery may increase survival for some liver cancer patients.
research The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study
The treatment combination is effective and generally safe for lung cancer.
research Patient-reported outcomes of adverse events after perioperative chemotherapy for breast cancer: A prospective observational study
Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.
research Patient-reported Outcomes of Adverse Events After Perioperative Chemotherapy for Breast Cancer: A Prospective Observational Study
Some side effects of breast cancer chemotherapy, like neuropathy and nail loss, can last long after treatment.
research Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.
research Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
Statins may be linked to reproductive organ conditions, and their risks should be monitored.
research Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.